Table 2.
Promoter TLR9 polymorphisms and their associations with the clinicopathological parameters at diagnosis.
| Clinicopathological parameters | TLR9-1486 | TLR9-1237 | ||
|---|---|---|---|---|
| TT | TC+CC | TT | TC+CC | |
| Age at diagnosis (n = 319) | ||||
| ≤35 | 35 (0.34) | 69 (0.66) | 74 (0.71) | 30 (0.29) |
| >35 | 71 (0.33) | 144 (0.67) | 164 (0.76) | 51 (0.24) |
| p | 0.910 | 0.324 | ||
| OR (CI 95%) | 1 | 1.028 (0.62-1.68) | 1 | 0.767 (0.45-1.30) |
| Sex (n = 319) | ||||
| Women | 35 (0.35) | 64 (0.65) | 68 (0.69) | 31 (0.31) |
| Men | 71 (0.32) | 149 (0.68) | 169 (0.77) | 51 (0.23) |
| p | 0.588 | 0.124 | ||
| OR (CI 95%) | 1 | 1.147 (0.70-1.89) | 1 | 0.662 (0.39-1.12) |
| Tumor size (n = 319) | ||||
| T1–T2 | 40 (0.28) | 101 (0.72) | 114 (0.81) | 27 (0.19) |
| T3–T4 | 65 (0.36) | 113 (0.64) | 123 (0.69) | 55 (0.31) |
| p | 0.124 | 0.017 | ||
| OR (CI 95%) | 1 | 0.688 (0.43-1.11) | 1 | 1.888 (1.11-3.19) |
| Lymph node status (n = 319) | ||||
| N0 | 19 (0.28) | 50 (0.72) | 54 (0.78) | 15 (0.22) |
| N+ | 86 (0.34) | 164 (0.66) | 183 (0.73) | 67 (0.27) |
| p | 0.283 | 0.394 | ||
| OR (CI 95%) | 1 | 0.725 (0.40-1.30) | 1 | 1.318 (0.69-2.49) |
| Metastasis (n = 306) | ||||
| M0 | 90 (0.32) | 195 (0.68) | 214 (0.75) | 71 (0.25) |
| M+ | 8 (0.38) | 13 (0.62) | 17 (0.81) | 4 (0.19) |
| p | 0.536 | 0.792a | ||
| OR (CI 95%) | 1 | 0.750 (0.30-1.87) | 1 | 0.709 (0.23-2.17) |
| Clinical stage (n = 318) | ||||
| SI-SII | 7 (0.29) | 17 (0.71) | 21 (0.88) | 3 (0.12) |
| SIII-SIV | 98 (0.33) | 196 (0.67) | 215 (0.73) | 79 (0.27) |
| p | 0.676 | 0.149a | ||
| OR (CI 95%) | 0.824 (0.33-2.05) | 1 | 2.572 (0.75-8.86) | |
aFisher's exact test; OR: odds ratio; CI: confidence interval.